FDA Approves Pancreatic Enzyme Replacement Product For Marketing In United States

The U.S. Food and Drug Administration announced that it has approved Creon (pancrelipase), a pancreatic enzyme replacement product designed to help patients with cystic fibrosis and others with exocrine pancreatic insufficiency (EPI) digest and absorb nutrients from foods. Creon is the first FDA-approved delayed-release pancreatic enzyme replacement product to be marketed in the United States as a result of the agency’s unapproved drugs initiative.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on May 11th, 2009